Histamine-Releasing Factor, a New Therapeutic Target in Allergic Diseases
Overview
Biophysics
Cell Biology
Molecular Biology
Affiliations
Histamine-releasing activities on human basophils have been studied as potential allergy-causing agents for four decades. An IgE-dependent histamine-releasing factor (HRF) was recently shown to interact with a subset of immunoglobulins. Peptides or recombinant proteins that block the interactions between HRF and IgE have emerged as promising anti-allergic therapeutics, as administration of them prevented or ameliorated type 2 inflammation in animal models of allergic diseases such as asthma and food allergy. Basic and clinical studies support the notion that HRF amplifies IgE-mediated activation of mast cells and basophils. We discuss how secreted HRF promotes allergic inflammation in vitro and in vivo complex disease settings.
Assesment of Salivary and Serum Levels of HBD2 in Patients with Chronic Angioedema.
Strajtenberger M, Lugovic-Mihic L, Stipic-Markovic A, Artukovic M, Glavina A, Pravica N J Clin Med. 2025; 13(24.
PMID: 39768474 PMC: 11728209. DOI: 10.3390/jcm13247552.
Win S, Horio F, Sato J, Motai Y, Seo H, Fujisawa S J Vet Med Sci. 2024; 87(1):1-12.
PMID: 39567007 PMC: 11735211. DOI: 10.1292/jvms.24-0186.
The multifaceted potential of as biomarker and therapeutic target.
Miao G, Yang Y, Yang X, Chen D, Liu L, Lei X Heliyon. 2024; 10(19):e38819.
PMID: 39397949 PMC: 11471257. DOI: 10.1016/j.heliyon.2024.e38819.
Katru S, Balakrishnan A, Munirathinam G, Hadadianpour A, Smith S, Kalyanasundaram R PLoS Negl Trop Dis. 2024; 18(2):e0011972.
PMID: 38354188 PMC: 10898765. DOI: 10.1371/journal.pntd.0011972.
Santamaria G, Cioce M, Rizzuto A, Fazio V, Viglietto G, Lucibello M Cancer Drug Resist. 2023; 6(3):447-467.
PMID: 37842235 PMC: 10571059. DOI: 10.20517/cdr.2023.21.